C
Carola Berking
Researcher at Ludwig Maximilian University of Munich
Publications - 324
Citations - 15009
Carola Berking is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 271 publications receiving 11675 citations. Previous affiliations of Carola Berking include University of Erlangen-Nuremberg & Wistar Institute.
Papers
More filters
Journal ArticleDOI
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen,Eliezer M. Van Allen,Nikhil Wagle,Nikhil Wagle,Antje Sucker,Daniel J. Treacy,Cory M. Johannessen,Eva M. Goetz,Chelsea S. Place,Chelsea S. Place,Amaro Taylor-Weiner,Steven R. Whittaker,Gregory V. Kryukov,Eran Hodis,Eran Hodis,Eran Hodis,Mara Rosenberg,Aaron McKenna,Aaron McKenna,Kristian Cibulskis,Deborah N. Farlow,Lisa Zimmer,Uwe Hillen,Ralf Gutzmer,Simone M. Goldinger,Selma Ugurel,Helen Gogas,Friederike Egberts,Carola Berking,Uwe Trefzer,Carmen Loquai,Benjamin Weide,Jessica C. Hassel,Stacey Gabriel,Scott L. Carter,Gad Getz,Gad Getz,Levi A. Garraway,Levi A. Garraway,Levi A. Garraway,Dirk Schadendorf +40 more
TL;DR: A "long tail" of new mitogen-activated protein kinase (MAPK) pathway alterations (MAP2K2, MITF) that confer RAF inhibitor resistance are discovered that may model subsequent resistance studies of BRAF(V600)-mutant melanoma.
Journal ArticleDOI
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.
Dmitri Lodygin,Valery Tarasov,Alexey Epanchintsev,Carola Berking,Tatjana Knyazeva,Henrike Körner,Piotr Knyazev,Joachim Diebold,Heiko Hermeking +8 more
TL;DR: The results show that miR-34a represents a tumor suppressor gene which is inactivated by CpG methylation and subsequent transcriptional silencing in a broad range of tumors.
Journal ArticleDOI
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto,Dirk Schadendorf,Carola Berking,Sanjiv S. Agarwala,Carla M.L. van Herpen,Paola Queirolo,Christian U. Blank,Axel Hauschild,J. Thaddeus Beck,Annie St-Pierre,Faiz Niazi,Simon Wandel,Malte Peters,Angela Zubel,Reinhard Dummer +14 more
TL;DR: MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments.
Journal ArticleDOI
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Lars Hofmann,Andrea Forschner,Carmen Loquai,Simone M. Goldinger,Lisa Zimmer,Selma Ugurel,Maria I. Schmidgen,Ralf Gutzmer,Jochen Utikal,Daniela Göppner,Jessica C. Hassel,Friedegund Meier,Julia K. Tietze,Ioannis Thomas,Carsten Weishaupt,Martin Leverkus,Renate Ursula Wahl,Ursula Dietrich,Claus Garbe,Michael C. Kirchberger,Thomas Eigentler,Carola Berking,Anja Gesierich,Angela M. Krackhardt,Dirk Schadendorf,Gerold Schuler,Reinhard Dummer,Lucie Heinzerling +27 more
TL;DR: Anti-PD1 antibodies can induce a plethora of irAEs, and the knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.
Journal ArticleDOI
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter,Rudolf Stadler,Cornelia Mauch,Werner Hohenberger,Norbert H. Brockmeyer,Carola Berking,Cord Sunderkötter,Martin Kaatz,Klaus-Werner Schulte,Percy Lehmann,Thomas Vogt,Jens Ulrich,Rudolf A. Herbst,Wolfgang Gehring,Jan-Christoph Simon,Ulrike Keim,Peter Martus,Claus Garbe +17 more
TL;DR: Results showed no difference in survival in patients treated with complete lymph node dissection compared with observation only, and complete lymph nodes dissection should not be recommended in patients with melanoma with lymph node micrometastases of at least a diameter of 1 mm or smaller.